NEW HORMONAL MEDICAMENTS AND THEIR USE FOR THE CORRECTION OF OESTROGENIC DEFICIENCIES

The present invention relates to the field of chemotherapy.

More precisely, it relates to new pharmaceutical compositions formed from an oestro-progestogenic combination for correction of oestrogen deficiencies during natural or artificial menopauses.

It particularly relates to a trisequential oestro-progestogenic combination, characterized in that it is made up of dosage units comprising only an oestrogen, dosage units comprising a combination of an oestrogen and a progestogen and dosage units comprising only an excipient

This combination is intended for administration by the oral route, and by using a particular formulation, it has been possible to be able to use oestradiol, that is to say natural oestrogen, by this route.


The progestogen used is a pure progestogen, such as nomegestrol acetate. As a result, it has been found that in such a combination, nomegestrol acetate does not cancel the natural effects of oestradiol, while allowing an artificial cycle of very good quality to be obtained in the menopausal woman.

It specifically relates to a new oestro-progestogenic medicament for correction of oestrogen deficiencies, characterized in that it is formed from three different types of dosage units, which are intended for use in successive sequences, that is to say 17β-oestradiol tablets, tablets comprising both 17β-oestradiol and nomegestrol acetate, and placebo tablets comprising only excipient.

These administration units are intended for administration in accordance with the following sequences:

- the 17β-oestradiol units for ten consecutive days

This Sheet Has Been Replaced



REPLACED SHEETS SG
Description : paged 1 to paged 13
Claim(s) : paged 14 to paged 15
Drawing(s) : paged — to paged —
Abstract : paged 16 to paged 16

- the units of the combination of 17β-oestradiol and nomegestrol acetate for fourteen consecutive days
- the placebo units for six days.

This Sheet Has Been Replaced



Consequently, the 17β-oestradiol tablets will be administered from day D1 to day D10, the tablets of the combination of 17β-oestradiol and nomegestrol acetate will be administered from day D11 to day D24, and the placebo tablets will be administered from day D25 to day D30.

According to a particular embodiment, the dosage units of oestradiol comprise an amount of active principle ranging from 1 to 3 mg, the dosage units containing the combination of 17β-oestradiol and nomegestrol acetate comprise an amount of 17β-oestradiol ranging from 1 to 3 mg and an amount of nomegestrol acetate ranging from 1.5 to 6 mg. Preferably, the dosage units of oestradiol comprise 1 to 2 mg of 17β-oestradiol and the dosage units of the oestro-progestogenic combination comprise 1 to 2 mg of 17β-oestradiol and 2.5 to 5 mg of nomegestrol acetate. Specifically, the optimum formulations comprise 1.5 mg of 17β-oestradiol or a combination of 1.5 mg of 17β-oestradiol and 3.75 mg of nomegestrol acetate.

This sequential mode of administration is intended to compensate functional disorders caused by hypoestrogenia associated with the menopause or with the premenopause. In particular, it is aimed at re-establishing an endometrial cycle in menopausal women, in particular those treated with 1 or 2 mg of 17β-oestradiol.

First clinical trial:

35 menopausal patients were studied in order to specify the best dose of nomegestrol acetate (N) to be associated with oestradiol to obtain menstrual cycles of quality with good luteal impregnation of the endometrium.

These patients were monitored in 6 different centres and received: initially, in an open trial, 17β-oestradiol by itself (in an amount of 1 or 2 mg/day, the gynaecologist having to adjust the dosages as a function of the clinical response) for 2 months; subsequently, under blind conditions, one of the following combinations for 4

months (oestradiol for 10 days, combination for the following 14 days, pause of 7 days).

- group A: O2 2 mg - N5 mg (n=6)
- group B: O2 2 mg - N 2.5 mg (n=8)
- group C: O2 1 mg - N 5 mg (n=9)
- group D: O2 1 mg - N 2.5 mg (n=7)
- group E: O2 1 mg - N 1.25 mg (n=5)

(O2: 17β-oestradiol N: nomegestrol acetate)

This Sheet Has Been Replaced

In 6 cases, the oestradiol dosage was adjusted and differed between the two treatment phases.

Two histological approaches were realized, the traditional one comprised semi-quantitative differentiation of the parameters of oestrogenization and of endometrial luteinization; the other comprised evaluation of the same parameters quantitatively with the aid of a computerized image analyzer system.

At the time of the study, the women of the various groups did not differ in any important parameter (age, height, weight, arterial pressure and length of time of the menopause).

The results obtained after 4 months of sequential treatment with 17β-oestradiol/nomegestrol acetate showed no statistically significant difference in a general manner between the groups:

- most often, no reappearance of hot flushes
- appearance of mastodynia more frequent in the two groups of 2 mg of oestradiol than in the three groups of 1 mg (4 cases out of 13 and 2 cases out of 18 respectively, these last two in group E).
- no pain on palpation of the breasts, no nodule was found during the six months of monitoring.
- occurrence of deprivation bleeding at the end of all the treatment cycles, except in 1 case of group A and in 2 cases of group C, groups having 5 mg of

nomegestrol acetate in their composition. The delay in the occurrence of bleeding after the treatment was stopped, its duration and its heaviness were recorded.

At the histological level, there was no significant difference between the two oestroprogestogen combinations, but they both differ from placebo by the existence of a higher number of endometria of secretory appearance, whereas there is a majority of proliferative endometria under placebo.

As regards the occurrence of clinical symptoms of hyperoestrogenia (mastodynia, pain and tension on palpation of the breasts, pelvic abdominal distension), there was no significant difference between the three groups.


The general tolerance is equivalent in the three groups. There is no variation in weight nor in systolic and diastolic arterial pressure after three months of treatment.

In the placebo group, 5 patients show one or more undesirable effects, 6 in the group of 1 mg of O2/2.5 mg of NOM and 3 in the group of 1.5 mg of O2/3.75 mg of NOM.

As regards the lipid parameters, the two progestogen combinations caused a significant drop in total cholesterol, LDL cholesterol and Lpa. In the group of 1.5 mg of O2/3.75 mg of NOM, a significant increase in apolipoprotein AI and an increase close to statistical significance in HDL cholesterol is found. There is no difference between the two combinations. The glycaemia and insulinaemia do not vary significantly.

As regards the coagulation factors, no significant change in antithrombin III, fibrinogen, fragment 1+2, prothrombin and total and free protein S was found. Protein C dominated slightly in the group of 1 mg of O2/2.5 mg of NOM, but did not vary significantly in the group of 1.5 mg of O2/3.75 mg of NOM. The plasminogen was increased significantly in the patients treated with the two oestroprogestogen combinations.

This Sheet Has Been Replaced



Thus, although no statistically significant difference could be detected between the various combinations, whatever the parameter studied, either clinical or histological, the results obtained suggest that group D gives the best results.

Second clinical trial:

In another trial, randomized over 57 patients divided into three groups, the following were administered in parallel to three groups of 19 patients in an amount of one tablet per day:

- tablets of 1 mg of 17β-oestradiol for 24 days combined with 2.5 mg of nomegestrol acetate for the last 14 days
- tablets of 1.5 mg of 17β-oestradiol for 24 days combined with 3.75 mg of nomegestrol acetate for the last 14 days
- a placebo

On inclusion, no significant difference between the 3 groups was recorded as regards age, length of time of the menopause, length of time of hot flushes and plasma concentrations of FSH and oestradiol.

The 3 treatments are effective on hot flushes, but the two active treatments differ from placebo as regards their effect on the intensity both at the 1st month and at the 3rd month. On the other hand, no significant difference between the two combinations was detected. As regards the frequency of hot flushes occurring during the night, there is a statistically significant difference between the group of 1.5 mg of O2/3.75 mg of NOM and the other two at the first month.

The global score of the climacteric symptomatology decreases significantly, whether at 1 or at 3 months. There is a statistically significant difference between each of the two oestroprogestogen combinations and placebo at 1 month and at 3 months.

At the level of the quality of the cycles, there is no difference regarding the frequency of the occurrence of deprivation bleeding, spotting or metrorrhagia

This Sheet Has Been Replaced



between the two treated groups. The same applies to the delay in the appearance of periods, their duration and their heaviness.

At the histological level, the two treated groups are identical but different from placebo ($p < 0.001$) with a majority of secretory endometria in the treated groups and a majority of proliferative endometria in the placebo group. No hyperplasia from endometria was found.

As regards the occurrence of mastodynias, abdomino-pelvic distension, pain and tension on palpation of the breasts, there is no significant difference between the three groups.

The general tolerance is equivalent in the three groups. There is no variation in weight nor in systolic and diastolic arterial pressure after three months of treatment. In the placebo group, 5 patients show one or more undesirable effects; 6 in the group of 1 mg of O2/2.5 mg of NOM and 3 in the group of 1.5 mg of O2/3.75 mg of NOM.

Regarding the lipid parameters (total cholesterol, C-HDL, C-LDL, apolipoproteins A1 and B, Lpa, triglycerides), only Lpa significatively drops in the group of 1 mg of 02/2,5 mg of NOM. In the group of 1,5 mg of 02/3,75 mg of NOM, the decrease of Lpa is close to significatively ($p = 0,055$), a significative increase in apolipoprotein A1 ($p = 0,005$) and increase of the C-HDL close to significativity, a significative decrease of total cholesterol ($p < 0,05$) of C-LDL ($p< 0,01$) and the ratio of atherogenic character CT/C-HDL and ApoB/ApoA_1 (respectively $p < 0,001$ and $p < 0,01$) are found. There is no difference between the two treated groups. The two treated groups only differ from placebo by the increase of apolipoproteins A_1. The glycaemia and insulinaemia do not significantly vary.

As regards the coagulation factors, antithrombin III and fibrinogen, no difference between each treated group and placebo group was found.

This Sheet Has Been Replaced

The plasma concentrations of oestradiol are lower with 1 mg of O2 (35.5 ± 6.67 pg/ml) than with 1.5 mg of O2 (72.5 ± 6.74 pg/ml). There is a significant difference ($p < 0.05$) in the group of 1.5 mg of O2/3.75 mg of NOM with respect to the placebo group and with respect to the group of 1 mg of O2/2.5 mg of NOM; as regards the sex hormone-binding protein: the increase is greater in the group of higher dosage.

IN CONCLUSION:

The two formulations are effective from the first month on climacteric symptomatology, and their efficacy differs from that of placebo. However, as regards the frequency of hot flushes during the night, there is a significant difference between the "high dose" group and the other two groups at the 1st month.

No difference between the three groups was recorded as regards gynaecological tolerance (mastodynia, quality of cycles and of periods) and general tolerance (weight and arterial pressure).

Third series of studies:

In a third series of clinical trials, a comparative study of the therapeutic efficacy of two oestroprogestogen combinations comprising different doses of 17β-oestradiol and nomegestrol acetate in comparison with placebo in the treatment of hot flushes in menopausal women was carried out.

This is a multicentre double-blind trial, randomized in three parallel groups:

83 patients were included in the study, 24 of whom were randomized in the placebo group, 29 in the group of 1 mg of O2/2.5 mg of NOM and 30 in the group of 1.5 mg of O2/3.75 mg of NOM, the study relating to menopausal women having an amenorrhoea of more than 3 months accompanied by hot flushes.

The products tested were:

- tablets of 1 mg of 17β-oestradiol for 24 days with 2.5 mg of nomegestrol acetate in the last 14 tablets

This Sheet Has Been Replaced

- tablets of 1.5 mg of 17β-oestradiol for 24 days with 3.75 mg of nomegestrol acetate in the last 14 tablets

in comparison with a placebo tablet administered for the same length of time.

On inclusion, analysis showed no difference between the three groups as regards the age of the patients, the length of time of the menopause and the level of FSH and oestradiol.

The results of this trial confirm the clinical data observed during the preceding trials, demonstrating the efficacy of the two oestroprogestogen combinations on climacteric symptomatology and on diurnal and, in particular, nocturnal hot flushes. There is no difference between them, but they prove to be superior to placebo in the majority of the clinical criteria studied. In the two groups under hormone treatment, no difference regarding the frequency of the occurrence of deprivation bleeding, its flow (d), its duration and its heaviness, nor for the frequencies of the occurrence of intercurrent bleeding (menorrhagia and spotting) is found. The tolerance was equivalent in the three groups studied.

Fourth clinical trial:

Comparative study of the therapeutic efficacy of a placebo and of two oestroprogestogenic combinations comprising different doses of 17β-oestradiol and nomegestrol acetate on the biological markers of bone restructuring in menopausal women.

The methodology is that of a multicentre double-blind trial randomized over 3 parallel groups.

The number of subjects is 117 (38 in the placebo group, 39 in the group of 1 mg of O2/2.5 mg of NOM and 40 in the group of 1.5 mg of O2/3.75 mg of NOM).
The subjects are menopausal women with an amenorrhoea of longer than 6 months.

PRODUCT, DOSE AND MODE OF ADMINISTRATION:

This Sheet Has Been Replaced



- tablets of 1 mg of 17β-oestradiol for 24 days with 2.5 mg of nomegestrol acetate in the last 14 tablets
- tablets of 1.5 mg of 17β-oestradiol for 24 days with 3.75 mg of nomegestrol acetate in the last 14 tablets
- placebo tablets

Results:

The clinical data collected in this trial confirm the results of the preceding trials, demonstrating that the two combinations reduce the frequency of hot flushes and enable an artificial cycle to be re-established.

No significant difference was found between the three groups as regards the clinical and biological tolerance.

The two oestroprogestogenic combinations tested differ from placebo in their ability to lower significantly the blood alkaline phosphatases and the pyridinoline/creatinine and deoxypyridinoline/creatinine ratios in the urine, whereas these parameters increase in the placebo group.

These results obtained in the short-term thus indicate that the hormone combinations tested are able to check the increased bone restructuring after the menopause. A beneficial effect in the prevention of postmenopausal osteoporosis can be predicted from this.

Intragroup analysis of the plasma markers of bone restructuring show a significant reduction in osteocalcin ($p < 0.02$) and a reduction close to significance in alkaline phosphatases in the group of 1 mg of O2/2.5 mg of NOM.

Comparison of the placebo group and the two treated groups reveals a significant difference ($p < 0.05$) as regards alkaline phosphatases and a difference close to significance ($p = 0.065$) as regards their osseous isoenzymes. There is no difference between the two treated groups.

This Sheet Has Been Replaced



Regarding the urinary markers, there is no difference between the three groups at the level of the calcium/creatinine and hydroxyproline/creatinine ratios. At the level of the pyridinoline/creatinine ratio, there is a significant difference between the group of 1 mg of O2/2.5 mg of NOM and the placebo group when the percentage variation with respect to the inclusion value is compared.

The global score of the climacteric symptomatology decreases significantly in the three groups, with no difference between them.

There is no difference between the two treated groups as regards the frequency of the occurrence of deprivation bleeding, spotting and metrorrhagia. However, two patients stopped the treatment because of metrorrhagia in the group of 1.5 mg of O2/3.75 mg of NOM, while none did in the other two groups. As regards the duration of periods, there is no difference between the two treated groups, whereas the delay in appearance is shorter in the group of 1 mg of O2/2.5 mg of NOM than in the high dose group ($p < 0.05$).

As regards mastodynia, abdomino-pelvic distension, pain and tension on palpation of the breasts, although their occurrence had a tendency to be more frequent in the group of 1.5 mg of O2/3.75 mg of NOM, the difference from the other two groups is not significant.

The tolerance is equivalent in the three groups, as is the incidence of discontinuations of treatment. One or more secondary effects were encountered in 5 patients of the placebo group, 13 of the group of 1 mg of O2/2.5 mg of NOM and 12 of the group of 1.5 mg of O2/3.75 mg of NOM.

The systolic and diastolic arterial pressures are not changed, whatever the treatment. There is a significant increase in weight ($p < 0.01$) in the group of 1.5 mg of O2/3.75 mg of NOM in the course of the trial; however, there is no significant difference between the three groups either in the weight level or in the arterial pressure.

This Sheet Has Been Replaced

As regards the biological parameters, there is an increase close to significance in the glycaemia in the group of 1 mg of O2/2.5 mg of NOM and a reduction close to significance in cholesterol in the placebo group. Comparison of the metabolic biological parameters did not demonstrate a significant difference between the three groups.

The plasma concentrations of oestradiol are lower with 1 mg of O2 (49.6 ± 8.09 pg/ml) than with 1.5 mg of O2 (60.8 ± 10.24 pg/ml).

IN CONCLUSION:

As regards the majority of the markers of bone restructuring, there is no difference between the two treated groups and the placebo group, with the exception of the percentage variation in the pyridinoline/creatinine ratio with respect to that at inclusion; there is a difference between the placebo group and the "low dose" group.

Example of a pharmaceutical composition according to the invention:

A/.Oestradiol tablets:

Oestradiol	1.500 g
Polyvinylpyrrolidone (Kollidon 25 from BASF)	13.500 g
Lactose	135.795 g
Microcrystalline cellulose (Avicel PH 101)	26.250 g
Glyceryl palmitostearate (Precirol)	2.775 g
Anhydrous colloidal silica (Aerosil 200)	1.000 g
Crospovidone (Polyplasdone XL)	4.000 g
Colouring agent	0.180 g

for 1,000 finished tablets of 0.185 g

This Sheet Has Been Replaced

Production is carried out in two stages:

a) **preparation of a premix**	0.4644
Oestradiol hemihydrate	
(with an average hydration of 3.2%)	4.050 kg
Polyvinylpyrrolidone	3.532 kg
Isopropyl alcohol	2.025 kg
Purified water	18.000 kg
Lactose	2.250 kg
Microcrystalline cellulose.	----------
	# 24.764 kg
Total after granulation and drying	

b) **Preparation of the final mixture:**	
	# 24.7640 kg
Granulated and dried premix	0.8325 kg
Glyceryl palmitostearate	0.300 kg
Anhydrous colloidal silica	1.200 kg
Crosslinked polyvinylpyrrolidone	5.6250 kg
Microcrystalline cellulose	22.7385 kg
Lactose	0.0540 kg
Colouring agent	---------
	55.5000 kg

This Sheet Has Been Replaced



B/.Tablets of oestradiol and nomegestrol acetate (1.5 mg of oestradiol and 3.75 mg of nomegestrol acetate per tablet):

Nomegestrol acetate	0.3750 kg
Premix according to Aa)	8.9285 kg
Lactose	6.400 kg
Avicel PH 101	1.8010 kg
Precirol ATO 5	0.2775 kg
Polyplasdone XL	0.6000 kg
Colouring agent	0.0180 kg
Aerosil 200	0.1000 kg

for 100,000 finished tablets of average weight 0.185 g.

This Sheet Has Been Replaced



CLAIMS

1. Use of an oestro-progestogenic mixture for treatment of oestrogen deficiencies in menopausal women, which comprises administration by the oral route of an oestrogen alone, of an oestrogen/progestogen combination, and finally of a placebo, throughout the entire duration of the month.

2. Use of the mixture according to claim 1, in which the oestrogen is 17β-oestradiol.

3. Use of the mixture according to claim 1, in which the progestogen is nomegestrol acetate.

4. Use of the oestro-progestogenic mixture according to one of claims 1 or 2, in which the oestrogen alone is administered in the form of tablets of 17β-oestradiol for a period of 10 days.

5. Use of the oestro-progestogenic mixture according to one of claims 1 to 3, in which the combination of an oestrogen and a progestogen is administered for 14 days consecutively.

6. Use of an oestro-progestogenic mixture according to claim 1, in which the placebo tablet is administered for six days consecutively.

7. An oestrogenic composition according to claim 1, in which the 17β-oestradiol is present in a dose ranging from 1 to 3 mg per unit dose.

8. An oestro-progestogenic composition according to claim 1, in which the 17β-oestradiol is present in a dose ranging from 1 to 3 mg and the nomegestrol acetate is present in a dose ranging from 1.5 to 6 mg.

9. A composition according to claim 7, in which the 17β-oestradiol is present in a dose ranging from 1 to 2 mg, and preferably in a dose of 1.5 mg.

This Sheet Has Been Replaced



10. A composition according to claim 7 and claim 8, in which the 17β-oestradiol is present in a dose ranging from 1 to 2 mg and the nomegestrol acetate is present in a dose ranging from 2.5 to 5 mg of nomegestrol acetate.

11. Process for the preparation of an oestrogenic composition according to claim 7, which consists in dispersing estradiol in a hydrophilic binding agent then adding an inert diluent agent and a binding agent of compression, in granulating the mass, in drying it and in grinding it, this mixture being, optionally, added with nomegestrol acetate and additive of compression to form tablets containing 17β-oestradiol and nomegestrol acetate.



This Sheet Has Been Replaced

ABSTRACT OF THE TECHNICAL CONTENT OF THE INVENTION

The present invention relates to the field of chemotherapy.

More precisely, it relates to a trisequential oestro-progestogenic combination, characterized in that it is made up of dosage units comprising only an oestrogen, dosage units comprising a combination of an oestrogen and a progestogen, and dosage units comprising only an excipient.

This trisequential mode of administration is intended for compensation of functional disorders caused by hypoestrogenia associated with the menopause or the premenopause.

REPLACEMENT SHEET

NEW HORMONAL MEDICAMENTS AND THEIR USE FOR THE CORRECTION OF OESTROGENIC DEFICIENCIES

The present invention relates to the field of chemotherapy.

More precisely, it relates to new pharmaceutical compositions formed from an oestro-progestogenic combination for correction of oestrogen deficiencies during natural or artificial menopauses.


It particularly relates to a trisequential oestro-progestogen, hormonal combination, characterized in that it is made up of dosage units comprising only an oestrogen, dosage units comprising a combination of an oestrogen and a progestogen and dosage units comprising only an excipient.


This combination is intended for administration by the oral route, and by using a particular formulation, it has been possible to be able to use oestradiol by this route. It is also possible to use an ester of oestradiol or a conjugation product of equine oestrogens, i.e a natural oestrogen.

As the used progestogen, it has been used a pure progestogen, such as nomegestrol acetate. As a result, it has been stated that in such a combination, nomegestrol acetate does not cancel the natural effects of oestradiol, while allowing an artificial cycle of very good quality to be obtained in the menopausal woman.

It specifically relates to a new oestro-progestogenic medicament for the correction of oestrogen deficiencies, characterized in that it is formed from three different types of dosage units, which are intended for use in successive sequences, that is to say tablets of 17β-oestradiol, an ester thereof or a conjugation product, tablets comprising both 17β-oestradiol an ester thereof or a conjugation product and nomegestrol acetate, and placebo tablets comprising only excipient.

This Sheet Has Been Replaced





These administration units are intended for administration in accordance with the following sequences:

- the units of 17β-oestradiol, an ester thereof or a conjugation product for ten consecutive days
- the units of the combination of 17β-oestradiol, an ester thereof or a conjugation product and nomegestrol acetate for fourteen consecutive days
- the placebo units for six days.

Consequently, the tablets containing 17β-oestradiol, an ester thereof or a conjugation product will be administered from day D1 to day D10, the tablets of the combination of 17β-oestradiol, an ester thereof or a conjugation product and nomegestrol acetate will be administered from day D11 to day D24, and the placebo tablets will be administered from day D25 to day D30.

According to a particular embodiment, the dosage units of oestradiol comprise an amount of active principle ranging from 1 to 3 mg and the dosage units containing the combination of 17β-oestradiol, an ester thereof or a conjugation product and nomegestrol acetate comprise an amount of 17β-oestradiol, an ester thereof or a conjugation product ranging from 1 to 3 mg and an amount of nomegestrol acetate ranging from 1.5 to 6 mg. Preferably, the dosage units of oestradiol comprise 1 to 2 mg of 17β-oestradiol, an ester thereof or a conjugation product and the dosage units of the oestro-progestogenic combination comprise 1 to 2 mg of 17β-oestradiol, an ester thereof or a conjugation product and 2.5 to 5 mg of nomegestrol acetate. Specifically, the optimal formulations comprise 1.5 mg of 17β-oestradiol, an ester thereof or a conjugation product or a combination of 1.5 mg of 17β-oestradiol, an ester thereof or a conjugation product and 3.75 mg of nomegestrol acetate.

This sequential mode of administration is intended to compensate functional disorders caused by hypoestrogenia associated with the menopause or with the premenopause. In particular, it is aimed at re-establishing an endometrial cycle in menopausal women, in particular those treated with 1 or 2 mg of 17β-oestradiol, an ester thereof or a conjugation product.

RECEIVED
10 JUN 1998

REPLACEMENT SHEET

First clinical trial:

35 menopausal patients were studied in order to specify the best dose of nomegestrol acetate (N) to be associated with oestradiol to obtain menstrual cycles of quality with good luteal impregnation of the endometrium.

These patients were monitored in 6 different centers and received : initially, in an open trial, 17β-oestradiol alone, an ester thereof or a conjugation product (in an amount of 1 or 2 mg/day, the gynaecologist having to adjust the dosages as a function of the clinical response) for 2 months; subsequently, under blind conditions, one of the following combinations for 4 months (oestradiol for 10 days, combination for the following 14 days, pause of 7 days).

- group A: O2 2 mg - N5 mg (n=6)
- group B: O2 2 mg - N 2.5 mg (n=8)
- group C: O2 1 mg - N 5 mg (n=9)
- group D: O2 1 mg - N 2.5 mg (n=7)
- group E: O2 1 mg - N 1.25 mg (n=5)

(O2: 17β-oestradiol N: nomegestrol acetate)


In 6 cases, the oestradiol dosage was adjusted and differed between the two treatment phases.

Two histological approaches were realized, the traditional one comprised semi-quantitative differentiation of the parameters of oestrogenization and of endometrial luteinization; the other comprised evaluation of the same parameters quantitatively with the aid of a computerized image analyzer system.

At the time of the study, the women of the various groups did not differ in any important parameter (age, height, weight, arterial pressure and length of time of the menopause).

The results obtained after 4 months of sequential treatment with 17β-oestradiol/nomegestrol acetate did not show any statistically significant difference in a general manner between the groups :

- most often, no reappearance of hot flushes




- appearance of mastodynia more frequent in the two groups with 2 mg of oestradiol than in the three groups of 1 mg (4 cases out of 13 and 2 cases out of 18 respectively, these last two in group E).
- no pain on palpation of the breasts, no nodule was found during the six months of monitoring.
- occurrence of deprivation bleeding at the end of all the treatment cycles, except in 1 case of group A and in 2 cases of group C, groups having 5 mg of nomegestrol acetate in their composition. The delay in the occurrence of bleeding after the treatment was stopped, its duration and its heaviness were recorded.

At the histological level, there was no significant difference between the two oestroprogestogen combinations, but they both differ from placebo by the existence of a higher number of endometria of secretory appearance, whereas there is a majority of proliferative endometria under placebo.

As regards to the occurrence of clinical symptoms of hyperoestrogenia (mastodynia, pain and tension on palpation of the breasts, pelvic abdominal distension), there was no significant difference between the three groups.
The general tolerance is equivalent in the three groups. There is no variation in weight nor in systolic and diastolic arterial pressure after three months of treatment.
In the placebo group, 5 patients show one or more side effects, 6 in the group of 1 mg of O2/2.5 mg of NOM and 3 in the group of 1.5 mg of O2/3.75 mg of NOM.

As regards to the lipidic parameters, the two progestogen combinations caused a significant drop in total cholesterol, LDL cholesterol and of Lipoprotein a (Lpa). In the group of 1.5 mg of O2/3.75 mg of NOM, a significant increase in Apolipoprotein A1 and an increase close to statistical significance in HDL cholesterol is found. There is no difference between the two combinations. The glycaemia and insulinaemia do not vary significantly.

As regards the coagulation factors, no significant change in antithrombin III, fibrinogen, fragment 1+2 of the prothrombin and of the total and free protein S was found. Protein C dominated slightly in the group of 1 mg of O2/2.5 mg of NOM, but did not vary significantly



in the group of 1.5 mg of O2/3.75 mg of NOM. The plasminogen was increased significantly in the patients treated with the two oestroprogestogen combinations.

Thus, although no statistically significant difference could be detected between the various combinations, whatever the parameter studied, either clinical or histological, the results obtained suggest that group D provides with the best results.

Second clinical trial:


In another trial, randomized over 57 patients divided into three groups, the following were administered in parallel to three groups of 19 patients in an amount of one tablet per day:

- tablets of 1 mg of 17β-oestradiol, an ester thereof or a conjugation product for 24 days combined with 2.5 mg of nomegestrol acetate for the last 14 days
- tablets of 1.5 mg of 17β-oestradiol, an ester thereof or a conjugation product for 24 days combined with 3.75 mg of nomegestrol acetate for the last 14 days
- a placebo

On inclusion, no significant difference between the 3 groups was recorded as regards to the age, length of time of the menopause, length of time of hot flushes and plasma concentrations of FSH and oestradiol.

The 3 treatments are effective on hot flushes, but the two active treatments differ from placebo as regards their effect on the intensity both at the 1st month and at the 3rd month. On the other hand, no significant difference between the two combinations was detected. As regards to the frequency of hot flushes occurring during the night, there is a statistically significant difference at the first month between the group of 1.5 mg of O2/3.75 mg NOM and the two others.

The global score of the climacteric symptomatology decreases significantly, whether at 1 or at 3 months. There is a statistically significant difference between each of the two oestroprogestogen combinations and placebo at 1 month and at 3 months.



At the level of the quality of the cycles, there is no difference regarding the frequency of the occurrence of deprivation bleeding, spotting or metrorrhagia between the two treated groups. The same applies to the delay in the appearance of periods, their duration and their heaviness.

At the histological level, there is no significant difference between the two eoestro-progestogen combinations, but they both differ from placebo by the existence of a higher number of endometria of secretory appearance, while there is a majority of proliferative endometria under placebo.

As regards to the occurrence of clinical symptoms of hyperoestrogenia (mastodynia, pain and tension on palpation of the breasts, abdomino-pelvic distension), there is no significant difference between the three groups.


The general tolerance is equivalent in the three groups. There is no variation in weight nor in systolic and diastolic arterial pressure after three months of treatment.

In the placebo group, 5 patients show one or more side effects; 6 in the group of 1 mg of O2/2.5 mg of NOM and 3 in the group of 1.5 mg of O2/3.75 mg of NOM.

As regards to the lipid parameters, the two progestative combinations caused a significant drop in total cholesterol, LDL cholesterol and Lpa. In the group of 1.5 mg 02/3.75 mg NOM, a significant increase in apolipoprotein A1 and an increase close to statistical significance in HDL cholesterol is found. There is no difference between the two combinations. The glycaemia and insulinaemia do not vary significantly.

As regards to the coagulation factors, no significant change in antithrombin III, fibrinogen, fragment 1+2 of prothrombin and total and free protein S was found. Protein C dominated slightly in the group of 1 mg 02/2.5 mg NOM, but did not vary significantly in the group of 1.5 mg 02/3.75 mg NOM. The plasminogen increased significantly in the patients treated with the two oestroprogestogen combinations.

The plasma concentrations of oestradiol are lower with 1 mg of O2 (35.5 ± 6.67 pg/ml) than with 1.5 mg of O2 (72.5 ± 6.74 pg/ml). There is a significant difference ($p < 0.05$) in the group of 1.5 mg O2/3.75 mg NOM with respect to the placebo group and with respect to the



group of 1 mg O2/2.5 mg NOM ; as regards the sex hormone-binding protein : the increase is greater in the group of higher dosage.

IN CONCLUSION:

The two formulations are effective from the first month on climacteric symptomatology, and their efficacy differs from that of placebo. However, as regards the frequency of hot flushes during the night, there is a significant difference between the "high dose" group and the other two groups at the 1st month.

No difference between the three groups was recorded as regards gynaecological tolerance (mastodynia, quality of cycles and of periods) and general tolerance (weight and arterial pressure).

Third series of studies:

In a third series of clinical trials, a comparative study of the therapeutic efficacy of two oestroprogestogen combinations comprising different doses of 17β-oestradiol and nomegestrol acetate in comparison with placebo, in the treatment of hot flushes in menopausal women was carried out.


This is a multicenter double-blind trial, randomized in three parallel groups:

83 patients were included in the study, 24 of whom were randomized in the placebo group, 29 in the group of 1 mg O2/2.5 mg NOM and 30 in the group of 1.5 mg O2/3.75 mg NOM, the study relating to menopausal women having an amenorrhoea of more than 3 months accompanied by hot flushes.

The products tested were:

- tablets of 1 mg of 17β-oestradiol for 24 days with 2.5 mg of nomegestrol acetate in the last 14 tablets
- tablets of 1.5 mg of 17β-oestradiol for 24 days with 3.75 mg of nomegestrol acetate in the last 14 tablets

in comparison with a placebo tablet administered for the same length of time.



REPLACEMENT SHEET

On inclusion, analysis showed no difference between the three groups as regards to the age of the patients, the length of time of the menopause and the level of FSH and oestradiol.

The results of this trial confirm the clinical data observed during the preceding trials, demonstrating the efficacy of the two oestroprogestogen combinations on climacteric symptomatology and on diurnal and, in particular, nocturnal hot flushes. There is no difference between them, but they prove to be superior to placebo in the majority of the clinical criteria studied. In the two groups under hormone treatment, no difference regarding the frequency of the occurrence of deprivation bleeding, its flow (d), its duration and its heaviness, nor for the frequencies of the occurrence of intercurrent bleeding (menorrhagia and spotting) is found. The tolerance was equivalent in the three groups studied.

Fourth clinical trial:

Comparative study of the therapeutic efficacy of a placebo and of two oestroprogestogenic combinations comprising different doses of 17β-oestradiol, an ester thereof or a conjugation product and nomegestrol acetate on the biological markers of bone restructuring in menopausal women.


The methodology is that of a multicenter double-blind trial randomized over 3 parallel groups.

The number of subjects is 117 (38 in the placebo group, 39 in the group of 1 mg O2/2.5 mg NOM and 40 in the group of 1.5 mg O2/3.75 mg NOM).

The subjects are menopausal women with an amenorrhoea of longer than 6 months.

PRODUCT, DOSE AND MODE OF ADMINISTRATION:

- tablets of 1 mg of 17β-oestradiol, an ester thereof or a conjugation product for 24 days with 2.5 mg of nomegestrol acetate in the last 14 tablets
- tablets of 1.5 mg of 17β-oestradiol, an ester thereof or a conjugation product for 24 days with 3.75 mg of nomegestrol acetate in the last 14 tablets
- placebo tablets



Results:

The clinical data collected in this trial confirm the results of the preceding trials, demonstrating that the two combinations reduce the frequency of hot flushes and enable an artificial cycle to be re-established.

No significant difference was found between the three groups as regards the clinical and biological tolerance.

The two oestroprogestogenic combinations tested differ from placebo in their ability to lower significantly the blood alkaline phosphatases and the pyridinoline/creatinine and deoxypyridinoline/creatinine ratios in the urine, whereas these parameters increase in the placebo group.


These results obtained in the short-term thus indicate that the hormone combinations tested are able to curb the bone restructuring increased after the menopause. A beneficial effect in the prevention of postmenopausal osteoporosis can be predicted from this.

Intragroup analysis of the plasma markers of bone restructuring show a significative reduction in osteocalcin ($p < 0.02$) and a reduction close to significance in alkaline phosphatases in the group of 1 mg O2/2.5 mg NOM.

Comparison of the placebo group and the two treated groups reveals a significative difference ($p < 0.05$) as regards alkaline phosphatases and a difference close to significativity ($p = 0.065$) as regards their osseous isoenzymes. There is no difference between the two treated groups.

Regarding the urinary markers, there is no difference between the three groups at the level of the calcium/creatinine and hydroxyproline/creatinine ratios. At the level of the pyridinoline/creatinine ratio, there is a significant difference between the group of 1 mg O2/2.5 mg NOM and the placebo group when the percentage variation with respect to the inclusion value is compared.

The global score of the climacteric symptomatology significatively decreases in the three groups, with no difference between them.



There is no difference between the two treated groups as regards the frequency of the occurrence of deprivation bleeding, spotting and metrorrhagia. However, two patients stopped the treatment because of metrorrhagia in the group of 1.5 mg O2/3.75 mg NOM, while none did in the other two groups. As regards the duration of periods, there is no difference between the two treated groups, whereas the delay in appearance is shorter in the group of 1 mg O2/2.5 mg NOM than in the high dose group ($p < 0.05$).

As regards mastodynia, abdomino-pelvic distension, pain and tension on palpation of the breasts, although their occurrence had a tendency to be more frequent in the group of 1.5 mg O2/3.75 mg NOM, the difference from the other two groups is not significative.

The tolerance is equivalent in the three groups, as is the incidence of discontinuations of treatment. One or more secondary effects were encountered in 5 patients of the placebo group, 13 of the group of 1 mg O2/2.5 mg NOM and 12 of the group of 1.5 mg O2/3.75 mg NOM.


The systolic and diastolic arterial pressures are not changed, whatever is the treatment. There is a significant increase in weight ($p < 0.01$) in the group of 1.5 mg O2/3.75 mg NOM in the course of the trial ; however, there is no significant difference between the three groups either in the weight level or in the arterial pressure.

As regards the biological parameters, there is an increase close to significativity in the glycaemia in the group of 1 mg O2/2.5 mg NOM and a reduction close to significativity in cholesterol in the placebo group. Comparison of the metabolic biological parameters did not demonstrate a significant difference between the three groups.

The plasma concentrations of oestradiol are lower with 1 mg of O2 (49.6 ± 8.09 pg/ml) than with 1.5 mg of O2 (60.8 ± 10.24 pg/ml).

IN CONCLUSION:

As regards the majority of the markers of bone restructuring, there is no difference between the two treated groups and the placebo group, with the exception of the percentage variation in the pyridinoline/creatinine ratio with respect to that at inclusion ; there is a difference between the placebo group and the "low dose" group.




Example of a pharmaceutical composition according to the invention:

A/.Oestradiol tablets:

Oestradiol	1.500 g
Polyvinylpyrrolidone (Kollidon 25 from BASF)	13.500 g
Lactose	135.795 g
Microcrystalline cellulose (Avicel PH 101)	26.250 g
Glyceryl palmitostearate (Precirol)	2.775 g
Anhydrous colloidal silica (Aerosil 200)	1.000 g
Crospovidone (Polyplasdone XL)	4.000 g
Colouring agent	0.180 g
for 1,000 finished tablets of 0.185 g	

Production is carried out in two stages:

a) preparation of a premix	
Oestradiol hemihydrate (with an average hydration of 3.2%)	0.4644
Polyvinylpyrrolidone	4.050 kg
Isopropyl alcohol	3.532 kg
Purified water	2.025 kg
Lactose	18.000 kg
Microcrystalline cellulose.	2.250 kg
Total after granulation and drying	# 24.764 kg



b) Preparation of the final mixture:

Granulated and dried premix	# 24.7640 kg
Glyceryl palmitostearate	0.8325 kg
Anhydrous colloidal silica	0.300 kg
Crosslinked polyvinylpyrrolidone	1.200 kg
Microcrystalline cellulose	5.6250 kg
Lactose	22.7385 kg
Colouring agent	0.0540 kg

	55.5000 kg

B/. Tablets of oestradiol and nomegestrol acetate (1.5 mg of oestradiol and 3.75 mg of nomegestrol acetate per tablet):

Nomegestrol acetate	0.3750 kg
Premix according to Aa)	8.9285 kg
Lactose	6.400 kg
Avicel PH 101	1.8010 kg
Precirol ATO 5	0.2775 kg
Polyplasdone XL	0.6000 kg
Colouring agent	0.0180 kg
Aerosil 200	0.1000 kg

for 100,000 finished tablets at average weight of 0.185 g.

10 JUN 1993

* C L M S *

CLAIMS

1. Use of an hormonal mixture for treatment of oestrogen deficiencies in menopausal women, which comprises administration by the oral route of an oestrogen by itself, of an oestrogen/progestogen combination, and finally of a placebo, throughout the entire duration of the month.

2. Use of the hormonal mixture according to claim 1, in which the oestrogen is 17β-oestradiol, an ester thereof or a conjugation product.

3. Use of the hormonal mixture according to claim 1, in which the progestogen is nomegestrol acetate.

4. Use of the hormonal mixture according to one of claims 1 or 2, in which the oestrogen by itself is administered in the form of tablets of 17β-oestradiol, an ester thereof or a conjugation product for a period of 10 days.

5. Use of the hormonal mixture according to one of claims 1 to 3, in which the combination of an oestrogen and a progestogen is administered for 14 days consecutively.

6. Use of an hormonal mixture according to claim 1, in which the placebo tablet is administered for six days consecutively.

7. An oestrogen composition according to claim 1, in which the 17β-oestradiol, an ester thereof or a conjugation product is present in a dose ranging from 1 to 3 mg per unit dose.

8. A composition according to claim 7, in which the 17β-oestradiol, an ester thereof or a conjugation product is present in a dose ranging from 1 to 2 mg, and preferably in a dose of 1.5 mg.

REPLACEMENT SHEET
10 JUN 1998

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

REPLACEMENT SHEET

9. An oestro-progestogen composition according to claim 1, in which the 17β-oestradiol, an ester thereof or a conjugation product is present in a dose ranging from 1 to 3 mg and the nomegestrol acetate is present in a dose ranging from 1.5 to 6 mg per unit dosage.

10. A composition according to claim 9, in which the 17β-oestradiol, an ester thereof or a conjugation product is present in a dose ranging from 1 to 2 mg and the nomegestrol acetate is present in a dose ranging from 2.5 to 5 mg.

11. Process for the preparation of an oestrogen composition according to claim 7, which comprises first preparing a premix composed of oestradiol hemihydrate, polyvinylpyrrolidone, isopropyl alcohol, purified water, lactose and microcrystalline cellulose, and then, after granulation and drying, preparing the final mixture composed of the granulated and dried premix, glyceryl palmito-stearate, anhydrous colloidal silica, crosslinked polyvinylpyrrolidone, microcrystalline cellulose, lactose and colouring agent.

12. Process for the preparation of an oestro-progestogen composition according to claim 9 which comprises adding to the premix defined in claim 11 nomegestrol acetate, conventional pharmaceutical excipients, a colouring agent and colloidal silica to form tablets comprising 17β-oestradiol and nomegestrol acetate.

REPLACEMENT SHEET
10 JUIN 1999

This Sheet Has Been Replaced

THIS SHEET HAS BEEN REPLACED

REPLACEMENT SHEET

REPLACEMENT SHEET
10 JUN 1998

CLAIMS

This Sheet Has Been Replaced

1. Trisequential hormonal, oestro-progestogenic combination for correction of estrogen deficiencies during natural or artificial menopause, intended for administration by the oral route throughout the entire duration of the month, characterized in that it is made up of dosage units comprising only an estrogen, dosage units comprising a combination of an estrogen and a progestagen and dosage units comprising only an inert diluent.

2. Trisequential hormonal combination according to claim 1, characterized in that the estrogen is estradiol, an estradiol ester or a conjuguated estrogen from equines.

3. Trisequential hormonal combination according to claim 1, characterized in that the progestogen is nomegestrol acetate.

4. Trisequential hormonal combination according to any one of claim 1 to 3, characterized in that the dosage unit comprising only an estrogen is administered in the form of tablets containing estradiol, an estradiol ester or a conjuguated estrogen from equines, for a period of 10 days consecutively.

5. Trisequential hormonal combination according to any one of claim 1 to 4, characterized in that the dosage unit comprising a combination of an estrogen and a progestogen is administered in the form of tablets containing estradiol, an estradiol ester or a conjuguated estrogen from equines with nomegestrol acetate for a period of 14 days consecutively.

6. Trisequential hormonal combination according to any one of claim 1 to 5, characterized in that the dosage unit comprising only an inert excipient is administered in the form of tablets for a period of 6 days consecutively.

* C L M S *

13 15

REPLACEMENT SHEETS SG
☐ Description : paged ... to paged ...
☑ Claim(s) : paged 13 to paged 15
☐ Drawing(s) : paged ... to paged ...
☐ Abstract : paged ... to paged ...
DATE OF RECEIPT 10-6-98

REPLACEMENT SHEET

7. Trisequential hormonal combination according to any one of claim 1 to 6, characterized in that the dosage unit comprising only estradiol, estradiol ester or conjuguated estrogens is present in a dose ranging from 1 to 3 mg per unit dosage.

8. Trisequential hormonal combination according to claim 7, characterized in that the dosage unit is present in a dose ranging from 1 to 2 mg per unit dosage, and preferably in a dose of 1,5 mg.

9. Trisequential hormonal combination according to any one of claim 1 to 8, characterized in that the dosage unit comprising a combination of estradiol, an estradiol ester or a conjuguated estrogen from equines with nomegestrol acetate is present in a dose ranging from 1 to 3 mg per unit dose for estradiol, estradiol ester or conjuguated estrogens from equines, and in a dose ranging from 1,5 to 6 mg per unit dosage for nomegestrol acetate.

10. Trisequential hormonal combination according to claim 9, characterized in that the dosage unit is present in a dose ranging from 1 to 2 mg per unit dose for estradiol, an estradiol ester or a conjuguated estrogen from equines, and in a dose ranging from 2,5 to 5 mg per unit dosage for nomegestrol acetate.

11. A process for the preparation of a trisequential hormonal combination according to any one of claims 1, 2, 4, 7 or 8, characterized in that the first step consists in preparing a premixture consisting of estradiol hemihydrate, an ester of estradiol hemihydrate or conjuguated estrogens from equines hemihydrate, polyvinylpyrrolidone, isopropyl alcohol, purified water, lactose, microcrystalline cellulose, then, after granulation and drying, in preparing the final mixture composed of the granulated and dried premixture, glyceryl palmitostearate, anhydrous colloidal silica, crosslinked polyvinylpyrrolidone, microcrystalline cellulose, lactose and colouring matter.

12. A process for the preparation of a trisequential hormonal combination according to any one of claims 1, 2, 3, 5, 9 or 10, characterized in that the premixture as defined in

REPLACEMENT SHEET
10 JUN 2003

This Sheet Has Been Replaced

claim 11 is added with nomegestrol acetate, pharmaceutical acceptable carriers, colouring matter and colloidal silica to form tablets of estradiol, of an estradiol ester or of conjuguated estrogens from equines with nomegestrol acetate.

13. Use of a trisequentiel hormonal combination according to any one of claims 1 to 10, for the realization of a drug intented to correction of oestrogen deficiencies during natural or artificial menopause.

This Sheet Has Been Replaced

10 JUN

* C L M S *

CLAIMS

1. Use of a trisequential hormonal, oestro-progestogenic combination for correction of estrogen deficiencies during natural or artificial menopause, which comprises administration by the oral route of dosage units comprising only an estrogen which are administered for a period of ten consecutive days, dosage units comprising a combination of an estrogen and a progestagen which are administered for a period of fourteen consecutive days and dosage units comprising only an inert diluent, which are administered for a period of six consecutive days throughout the entire duration of the month.

2. Use of the trisequential hormonal, oestro-progestogenic combination according to claim 1, characterized in that the oestrogen is estradiol, an estradiol ester or a conjuguated estrogen from equines.

3. Use of the trisequential hormonal, oestro-progestogenic combination according to claim 1, characterized in that the progestogen is nomegestrol acetate.

4. Use of the trisequential hormonal, oestro-progestogenic combination according to one of claims 1 or 2, characterized in that the dosage unit comprising only an estrogen is administered in the form of tablets containing estradiol, an estradiol ester or a conjuguated estrogen from equines.

5. Use of the trisequential hormonal, oestro-progestogenic combination according to one of claims 1 to 3, characterized in that the dosage unit comprising a combination of an estrogen and a progestogen is administered in the form of tablets containing estradiol, an estradiol ester or a conjuguated estrogen from equines with nomegestrol acetate.

REPLACEMENT SHEET
16 MAY 2000

REPLACEMENT SHEETS SG
☐ Description : paged .... to paged ....
☑ Claim(s) : paged 13 to paged 15
☐ Drawing(s) : paged .... to paged ....
☐ Abstract : paged .... to paged ....
DATE OF RECEIPT 16.5.00

6. Use of the trisequential hormonal, oestro-progestogenic combination according to claim 1, characterized in that the dosage unit comprising only an inert excipient is administered in the form of tablets.

7. Use of the trisequential hormonal, oestro-progestogenic combination according to claim 1, characterized in that the dosage unit comprising only estradiol, estradiol ester or conjugated estrogens is present in a dose ranging from 1 to 3 mg per unit dosage.

8. Use of the trisequential hormonal, oestro-progestogenic combination according to claim 7, characterized in that the dosage unit is present in a dose ranging from 1 to 2 mg per unit dosage, and preferably in a dose of 1,5 mg.

9. Use of the trisequential hormonal, oestro-progestogenic combination according to claim 1, characterized in that the dosage unit comprising a combination of estradiol, an estradiol ester or a conjuguated estrogen from equines with nomegestrol acetate is present in a dose ranging from 1 to 3 mg per unit dose for estradiol, estradiol ester or conjuguated estrogens from equines, and in a dose ranging from 1,5 to 6 mg per unit dosage for nomegestrol acetate.

10. Use of the trisequential hormonal, oestro-progestogenic combination according to claim 9, characterized in that the dosage unit is present in a dose ranging from 1 to 2 mg per unit dose for estradiol, an estradiol ester or a conjuguated estrogen from equines, and in a dose ranging from 2,5 to 5 mg per unit dosage for nomegestrol acetate.

11. A process for the preparation of a trisequential hormonal combination according to any one of claims 1, 2. 4, 7 or 8, characterized in that the first step consists in preparing a premixture consisting of estradiol hemihydrate, an ester of estradiol hemihydrate or conjuguated estrogens from equines hemihydrate, polyvinylpyrrolidone, isopropyl alcohol, purified water, lactose, microcrystalline

16 MAY 2000

cellulose, then, after granulation and drying, in preparing the final mixture composed of the granulated and dried premixture, glyceryl palmitostearate, anhydrous colloidal silica, crosslinked polyvinylpyrrolidone, microcrystalline cellulose, lactose and colouring matter.

12.A process for the preparation of a trisequential hormonal combination according to any one of claims 1, 2, 3, 5, 9 or 10, characterized in that the premixture as defined in claim 11 is added with nomegestrol acetate, pharmaceutical acceptable carriers, colouring matter and colloidal silica to form tablets of estradiol, of an estradiol ester or of conjuguated estrogens from equines with nomegestrol acetate.

REPLACEMENT SHEET
16 MAY 2000

~~NEW HORMONAL MEDICAMENTS~~

~~AND THEIR USE FOR THE CORRECTION OF OESTROGENIC~~

~~DEFICIENCIES~~

NEW HORMONAL MEDICAMENTS AN USE THEREOF FOR CORRECTING OESTROGEN DEFICIENCIES

The present invention relates to the field of chemotherapy.

More precisely, it relates to new pharmaceutical compositions formed from an oestro-progestogenic combination for correction of oestrogen deficiencies during natural or artificial menopauses.

It particularly relates to a trisequential oestro-progestogen, hormonal combination, characterized in that it is made up of dosage units comprising only an oestrogen, dosage units comprising a combination of an oestrogen and a progestogen and dosage units comprising only an excipient.

This combination is intended for administration by the oral route, and by using a particular formulation, it has been possible to be able to use oestradiol by this route. It is also possible to use an ester of oestradiol or a conjugation product of equine oestrogens, i.e a natural oestrogen.

As the used progestogen, it has been used a pure progestogen, such as nomegestrol acetate. As a result, it has been stated that in such a combination, nomegestrol acetate does not cancel the natural effects of oestradiol, while allowing an artificial cycle of very good quality to be obtained in the menopausal woman.

It specifically relates to a new oestro-progestogenic medicament for the correction of oestrogen deficiencies, characterized in that it is formed from three different types of dosage units, which are intended for use in successive sequences, that is to say tablets of 17β-oestradiol, an ester thereof or a conjugation product, tablets comprising both 17β-oestradiol an ester thereof or a conjugation product and nomegestrol acetate, and placebo tablets comprising only excipient.

REPLACEMENT SHEET
11 AUG 2000

This Sheet Has Been Replaced

REPLACEMENT SHEET

NEW HORMONAL MEDICAMENTS AND USE THEREOF FOR CORRECTING OESTROGEN DEFICIENCIES

The present invention relates to the field of chemotherapy.

More precisely, it relates to new pharmaceutical compositions formed from an oestro-progestogenic combination for correction of oestrogen deficiencies during natural or artificial menopauses.

It particularly relates to a trisequential oestro-progestogen, hormonal combination, characterized in that it is made up of dosage units comprising only an oestrogen, dosage units comprising a combination of an oestrogen and a progestogen and dosage units comprising only an excipient.

This combination is intended for administration by the oral route, and by using a particular formulation, it has been possible to be able to use oestradiol by this route. It is also possible to use an ester of oestradiol or a conjugation product of equine oestrogens, i.e. a natural oestrogen.

As the used progestogen, it has been used a pure progestogen, such as nomegestrol acetate. As a result, it has been stated that in such a combination, nomegestrol acetate does not cancel the natural effects of oestradiol, while allowing an artificial cycle of very good quality to be obtained in the menopausal woman.

It specifically relates to a new oestro-progestogenic medicament for the correction of oestrogen deficiencies, characterized in that it is formed from three different types of dosage units, which are intended for use in successive sequences, that is to say tablets of 17β-oestradiol, an ester thereof or a conjugation product, tablets comprising both 17β-oestradiol an ester thereof or a conjugation product and nomegestrol acetate, and placebo tablets comprising only excipient.

REPLACEMENT SHEET
12 JAN 2001